PT Jayamas Medica Industri Tbk (OMED.JK)
IDR 184.0
(-2.14%)
IDR 184.0
(-2.14%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 134.35 Billion | 92.61 Billion | 505.1 Billion | 278.73 Billion | 174.71 Billion |
| Net Income | 259.35 Billion | 285.78 Billion | 562.69 Billion | 685.5 Billion | 226.2 Billion |
| Depreciation & Amortization | 56.52 Billion | 41.21 Billion | 34.97 Billion | 16.89 Billion | 13.6 Billion |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | - | - | - | - | - |
| Other non-cash items | -181.53 Billion | -234.37 Billion | -92.55 Billion | -423.66 Billion | -65.09 Billion |
| Investing Cash Flow | 264.59 Billion | -495.09 Billion | -187.05 Billion | -49.84 Billion | -15.07 Billion |
| Investments in PPE | -156.44 Billion | -75.37 Billion | -82.78 Billion | -52.44 Billion | -14.49 Billion |
| Acquisitions | - | - | - | - | - |
| Investment purchases | -15.91 Billion | -419.47 Billion | -105 Billion | -5 Million | - |
| Sales/Maturities of investments | 436.35 Billion | - | 690 Million | - | - |
| Other Investing Activities | 185.14 Million | -251.91 Million | -104.33 Billion | 120.79 Million | -580.3 Million |
| Financing Cash Flow | -110.57 Billion | 493.48 Billion | -282.97 Billion | 150.82 Billion | -1.69 Billion |
| Debt repayment | -25.3 Billion | -36.34 Billion | -17.97 Billion | -159.2 Billion | -1.69 Billion |
| Dividends payments | -85.77 Billion | -250 Billion | -255 Billion | - | - |
| Common Stock Repurchased | - | - | - | -5.5 Billion | - |
| Common Stock Issuance | - | 780.57 Billion | - | - | - |
| Other Financing Activities | 505 Million | 779.82 Billion | -10 Billion | - | - |
| Accounts receivables | - | - | - | - | - |
| Accounts payables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other working capital | - | - | - | - | - |
| Cash at beginning of period | 830.54 Billion | 732.84 Billion | 697.02 Billion | 316.21 Billion | 158.3 Billion |
| Cash at end of period | 1120.57 Billion | 830.54 Billion | 732.84 Billion | 697.02 Billion | 316.21 Billion |
| Capital Expenditure | -156.44 Billion | -75.37 Billion | -82.78 Billion | -52.44 Billion | -14.49 Billion |
| Effect of forex changes on cash | 1.65 Billion | 6.7 Billion | 731.57 Million | 1.09 Billion | -38.15 Million |
| Net cash flow / Change in cash | 290.02 Billion | 97.7 Billion | 35.81 Billion | 380.81 Billion | 157.91 Billion |
| Free Cash Flow | -22.08 Billion | 17.24 Billion | 422.32 Billion | 226.28 Billion | 160.22 Billion |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 80.48 Billion | 63.46 Billion | 76.97 Billion | 259.35 Billion | 71.77 Billion | 54.18 Billion |
| Depreciation & Amortization | 14.1 Billion | 13.42 Billion | 16.5 Billion | 56.52 Billion | 12.97 Billion | 13.26 Billion |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | - | - | - |
| Other non-cash items | 17.63 Billion | -24.78 Billion | 58.42 Billion | -181.53 Billion | 9.48 Billion | -56.26 Billion |
| Investing Cash Flow | -76.26 Billion | -15.68 Billion | -39.84 Billion | 264.59 Billion | -42.58 Billion | -130 Billion |
| Investments in PPE | -22.29 Billion | -23.05 Billion | -46.73 Billion | -156.44 Billion | -34.93 Billion | -55.3 Billion |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -41.85 Billion | -4.73 Billion | - | -15.91 Billion | - | -34.08 Billion |
| Sales/Maturities of investments | - | 12.11 Billion | - | 436.35 Billion | - | -40.62 Billion |
| Other Investing Activities | -53.97 Billion | 7.35 Billion | 6.89 Billion | 185.14 Million | -6.11 Billion | -74.7 Billion |
| Financing Cash Flow | -526.02 Million | -13.38 Billion | -21.26 Billion | -110.57 Billion | 401.23 Million | -86.08 Billion |
| Debt repayment | -526.02 Million | -13.38 Billion | - | -25.3 Billion | - | -817.65 Million |
| Dividends payments | - | - | - | -85.77 Billion | - | -85.77 Billion |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -526.02 Million | - | -21.26 Billion | 505 Million | 401.23 Million | 505 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 1143.11 Billion | 1120.57 Billion | 1024.12 Billion | 830.54 Billion | 967 Billion | 1174.64 Billion |
| Cash at end of period | 1186.06 Billion | 1143.11 Billion | 1120.57 Billion | 1120.57 Billion | 1024.12 Billion | 967 Billion |
| Capital Expenditure | -22.29 Billion | -23.05 Billion | -46.73 Billion | -156.44 Billion | -34.93 Billion | -55.3 Billion |
| Effect of forex changes on cash | 7.51 Billion | -483.71 Million | 5.65 Billion | 1.65 Billion | 5.06 Billion | -2.72 Billion |
| Net cash flow / Change in cash | 42.94 Billion | 22.54 Billion | 96.45 Billion | 290.02 Billion | 57.11 Billion | -207.63 Billion |
| Free Cash Flow | 89.93 Billion | 29.04 Billion | 105.16 Billion | -22.08 Billion | 59.29 Billion | -44.11 Billion |
CSCCF
0GC0
1003
LUMAXIND
CGTX
FMK